P-283 How To Effectively Administer Belantamab Mafodotin: Knowledge Gained From the Phase 1/2 BelaRd Study in Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma

Article2023

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis‐Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A Dimopoulos

Article2023

Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.

Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A Dimopoulos

Article2023

P-123 Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis‐Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A Dimopoulos

Article2024

Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Ioannis V. Kostopoulos, Rodanthi‐Eleni Syrigou, Evangelos Eleutherakis‐Papaiakovou, Stavros Gkolfinopoulos, Ourania Tsitsilonis, Efstathios Kastritis, Meletios A Dimopoulos

Article2025

Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Nikolaos Kanellias, Eirini Solia, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Giorgos Psarros, Efstathios Kastritis, Meletios A Dimopoulos

Discussion(0)

Related publications

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY

Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.

P-123 Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study

Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study

Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study